氨基观察-创新药组原创出品作者 | 黄恺Claudin 18.2又要被颠覆了。1月6日,新桥生物宣布,其Claudin 18.2x 4-1BB双特异性抗体Givastomig联合纳武利尤单抗及化疗方案(mFOLFOX6)用于一线(1L)治疗HER2阴性转移的胃癌患者的Ib期联合疗法研究,取得积极的数据。本次公布的数据,包括并整合了Ib期研究中接受8 mg/kg或12 mg/kg ...
Source Link氨基观察-创新药组原创出品作者 | 黄恺Claudin 18.2又要被颠覆了。1月6日,新桥生物宣布,其Claudin 18.2x 4-1BB双特异性抗体Givastomig联合纳武利尤单抗及化疗方案(mFOLFOX6)用于一线(1L)治疗HER2阴性转移的胃癌患者的Ib期联合疗法研究,取得积极的数据。本次公布的数据,包括并整合了Ib期研究中接受8 mg/kg或12 mg/kg ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.